Dr. Kennon-McGill’s work primarily focuses on prenatal drug exposure and its effects on the neurodevelopment of children who were exposed in utero. Her current focus is prenatal cannabis and cannabinoid use and their effects on brain development and neurobehavioral outcomes in children. She utilizes liquid chromatography-mass spectrometry (LC-MS/MS) to quantify THC and CBD metabolites in the maternal, umbilical cord, and neonatal blood and correlates levels of exposure to various neurodevelopmental outcome measures.